Orris
attachment
attachment

Explain the origin of quinolones

Reading File
analyse_media
Finding Sources
Finding Sources
Searching the Web

history discovery of nalidixic acid George Lesher chloroquine synthesis quinolone antibiotics origin

Origin of Quinolones

The accidental discovery
Quinolones originated from antimalarial research, not antibacterial research. In 1962, George Lesher and coworkers at Sterling Drug (Sterling-Winthrop Research Institute) were trying to synthesize chloroquine, an antimalarial drug. During this synthesis process, they isolated a by-product/impurity in a distillate that turned out to have antibacterial activity. That compound was nalidixic acid, the first quinolone - Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 251; Lippincott Illustrated Reviews Pharmacology.
This traces back further to the wartime and postwar effort to develop synthetic antimalarials as substitutes for quinine (derived from cinchona bark). Chloroquine itself had been discovered by Hans Andersag in 1934 while working on quinine-based structures. Sterling's chemists were extending this line of work when the nalidixic acid impurity turned up, essentially a "happy accident" in drug discovery.
Structure
Nalidixic acid is chemically a naphthyridone (1-ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid), closely related to the quinolone nucleus. It became the prototype for the entire quinolone class, and its core 4-oxo-quinoline/naphthyridine-carboxylic acid scaffold is what all later quinolones and fluoroquinolones were built from - matching the structure shown in your slide.
Clinical introduction and evolution
  • 1962-1964: Nalidixic acid discovered and clinically introduced by Sterling Drug in the US, used for uncomplicated urinary tract infections caused by gram-negative organisms. This marks the 1st generation of quinolones.
  • Over the following two decades, chemists modified the quinolone nucleus systematically - adding substituents at various ring positions - which:
    • Broadened the antibacterial spectrum (adding gram-positive and Pseudomonas coverage)
    • Improved pharmacokinetics (absorption, half-life, tissue penetration)
    • Improved chemical stability
  • The key breakthrough was the addition of a fluorine atom at the C-6 position of the quinolone ring in the 1980s, producing the fluoroquinolones (norfloxacin, ciprofloxacin, ofloxacin, levofloxacin, etc.). These were far more potent, had broader spectra, and better oral bioavailability than nalidixic acid - Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 251.
  • This progressive modification is why later generations (2nd, 3rd, 4th) are described in your slide as gaining increasing gram-positive, atypical, and anaerobic/mycobacterial coverage while retaining the core naphthyridone/quinolone scaffold inherited from nalidixic acid.
Summary of the lineage Cinchona bark (quinine) → synthetic antimalarials (chloroquine, 1934) → accidental isolation of nalidixic acid as a chloroquine synthesis by-product (Lesher et al., 1962) → 1st generation quinolones → fluorination and structural optimization → 2nd/3rd/4th generation fluoroquinolones in clinical use today.
A brief evidence check: I ran a recent literature scan (systematic reviews/meta-analyses, last 2 years) specifically on this historical/origin question and found no new results, which is expected since this is settled pharmacological history rather than an active clinical evidence question. No contradicting or updating evidence to flag.
This is a shared conversation. Sign in to Orris to start your own chat.